## **Primary Care surveillance of discharged prostate cancer patients**

Clinical Management Situation	Patient Status		Desirable PSA Level		Frequency of PSA Te	esting	Evidence of loss of control of disease/need to refer back
Watchful waiting not on treatment  Localised cancer on	a) Possible prostate cancer but diagnosis not established on biopsy b) Asymptomatic but elderly or with substantial co- morbidity with an established diagnosis Older Patient with confirmed		Maintain stability at/around level of time of referral back to GP for follow up		Every 6 months. If rising repeat in 3 months	•	<ul> <li>Rising PSA level on 3 consecutive tests</li> <li>PSA rise, doubling from baseline (discharge level) in 6 months</li> <li>Evidence of distant or local recurrence</li> </ul>
treatment or previously	stable localised cancer						
treated							
Known metastatic cancer	Known metastatic prostate cancer but asymptomatic and stable on LHRH agonists						
Post radical	Younger age group having		High sensitivity PSA stable		Yearly		
radiotherapy/brachytherapy	had 'curative' treatment for		and below 0.05ng/ml		,		
Post radical prostatectomy	localises disease +/- hormone therapy and discharged at 5 years 'cured'		High sensitivity PSA stable and below 0.05ng/ml				
						•	
			Untreated ag	e specific PSA			
40-49 years Less than		Less than 2.0ng/ml	60-69 years		Less than 4.0ng/ml		an 4.0ng/ml
50-59 years	<b>0-59 years</b> Less than 3.0ng/ml		70-80 years			Less than 6.0ng/ml	
If patient over	80 year	s the PSA may be irrelev	vant but conside	er referral to Uro	ologist for palliative tre	atment if	f symptomatic